This content is from: Features

Why biosimilars are being held back in the US

No biosimilar producers have made use of an accelerated US approval pathway introduced in 2010, and now the first case has found against a biosimilar for Enbrel. George Yu and Jason Harp explain where this leaves the industry

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial